Galena Biopharma, Inc. (NASDAQ:GALE)
| CAPS Rating |
|
|---|
GALE
VS S&P 500 (SPY)
GALE News and Commentary
- A Short Interview With Galena CEO Dr. Ahn To Address Recent Concerns – SeekingAlpha
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 1 – SeekingAlpha
- NeuVax Founder Dr. Peoples Eliminates Speculation For Facts – SeekingAlpha
- Darling Dendreon Takes Hits As Speculators Continue To Bet On Immunotherapy Plays – SeekingAlpha
- An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABP – 247wallst
- Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CY – 247wallst
- Drug Maker Prices Secondary Offering (GALE) – 247wallst
- Roche feeling the heat from Galena breast cancer drug – Blog at The Motley Fool
- How to Trade Dendreon Ahead of Earnings, and Other Biotechs to Watch – Minyanville
How do you think GALE will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
100
Outperform
10
Underperform
All-Star Players
12
Outperform
5
Underperform
Wall Street
0
Outperform
0
Underperform
RSS Headlines
Fool UK
